Skip to content

Detection of Acute Renal Failure Using Hospital Coding Data

Acute Kidney Injury and Drug-related Acute Kidney Injury : Use of Hospital Coding Data for Their Identification

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04923750
Acronym
IRA-PMSI
Enrollment
498
Registered
2021-06-11
Start date
2021-06-03
Completion date
2023-12-31
Last updated
2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Renal Failure, Iatrogenic Effect, Uremic Toxin

Keywords

acute renal failure, iatrogenic, pharmaco epidemiology, medico economy, Uremic toxin, PMSI

Brief summary

AKI is a rapid and usually reversible impairment of kidney function that is life-threatening in the short term well described by the Kidney Disease: Improving Global Outcomes - KDIGO classification of 2012. Whatever etiology of acute renal failure, drug iatrogeny still has its place. Hospital data from the information systems medicalization program (PMSI) can be used for epidemiological research. No study has yet been performed on these data to assess drug-related AKI. However, it should be remembered that these databases were not originally designed for research purposes but for reimbursement of care. Therefore, before conducting a large-scale study, it remains important to determine the validity and representativeness of the codes used for coding the studied events. The objective of this project is therefore to validate the use of hospital coding to identify AKI.

Detailed description

Acute kidney injury (AKI) is a rapid and usually reversible impairment of kidney function that is life-threatening in the short term; the grades of which are defined by the KDIGO classification of 2012. Whatever etiology of acute renal failure, drug iatrogeny still has its place. Data literature indicate that AKI affects more than one in five adults worldwide while hospitalized, with an associated mortality rate above 20%. It constitutes a non-negligible part of hospitalizations when it is acquired in the community, and also causes prolongations of hospitalizations, and therefore an increase in the cost for the hospital. Hospital data from the information systems medicalization program (PMSI) is a device that is part of the reform of the French health system with the aim of reducing inequalities in resources between health establishments. Since 2007, it has been possible to link all discharge summaries for one patient. The diagnoses identified during hospitalization are coded according to the 10th edition of the International Classification of Diseases (ICD-10). The data from PMSI coding can be used for epidemiological research. The majority of studies were related to patients with chronic kidney disease, especially dialysis patients. No study has yet been performed on these data to assess drug-related AKI. However, it should be remembered that these databases were not originally designed for research purposes but for reimbursement of care. Therefore, before conducting a large-scale study, it remains important to determine the validity and representativeness of the codes used for coding the events to be studied.

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over \> = 18 years old * Patients hospitalized at the CHU Amiens Picardie during 6 months * patients for which at least two plasma creatinine measurements were taken during the hospitalization

Exclusion criteria

* Patients under \<18 years old * Patients on dialysis for chronic renal failure * Hospitalization for a kidney transplant * Postpartum AKI

Design outcomes

Primary

MeasureTime frame
identification of AKIs by codes in the PMSI databasetwo years
identification of drug-induced AKIs by codes in the PMSI databasetwo years

Secondary

MeasureTime frameDescription
Variation of performance of the codes according to hospitalization servicetwo years
Identification of the type of drugs involved in drug-induced AKItwo years
Variation of performance of the codes according to the characteristics of the AKItwo years
Identification of AKI Risk factorstwo years
incidence of drug-induced AKItwo yearsincidence of drug-induced AKI (community-based and hospital-induced AKI (AKI-AH))
Variation of performance of the codes according to KDIGO gradetwo years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026